Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage - Test2 - elhamkhani - TriplyDB

Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage

Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage

http://www.wikidata.org/entity/Q35449198

about

Iron chelators for acute stroke Intracerebral Hemorrhage, Oxidative Stress, and Antioxidant Therapy Oxidative Stress in Intracerebral Hemorrhage: Sources, Mechanisms, and Therapeutic Targets Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury Antioxidants: The new frontier for translational research in cerebroprotection Intracerebral Hemorrhage: Perihemorrhagic Edema and Secondary Hematoma Expansion: From Bench Work to Ongoing Controversies Clinical trials for neuroprotective therapies in intracerebral hemorrhage: a new roadmap from bench to bedside.Preclinical Studies and Translational Applications of Intracerebral Hemorrhage.Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate The relationship between the serum levels of ferritin and the radiological brain injury indices in patients with spontaneous intracerebral hemorrhage The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage.Therapeutic strategies in acute intracerebral hemorrhage.Antioxidant strategies in neurocritical care Brain iron metabolism and brain injury following subarachnoid hemorrhage: iCeFISH-pilot (CSF iron in SAH).Adaptive trial designs: a review of barriers and opportunities Role of iron in brain lipocalin 2 upregulation after intracerebral hemorrhage in rats.Effect of iron chelators on methemoglobin and thrombin preconditioning Hematoma expansion following acute intracerebral hemorrhage.Brain iron deposition in white matter hyperintensities: a 3-T MRI study.Heme oxygenase-1-mediated neuroprotection in subarachnoid hemorrhage via intracerebroventricular deferoxamine.Ferric iron chelation lowers brain iron levels after intracerebral hemorrhage in rats but does not improve outcome.Intracerebral haemorrhage: mechanisms of injury and therapeutic targets.New avenues for treatment of intracranial hemorrhage.High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods.Progress in translational research on intracerebral hemorrhage: is there an end in sight?Imaging PEG-like nanoprobes in tumor, transient ischemia, and inflammatory disease models Iron and intracerebral hemorrhage: from mechanism to translation.Role of iron in ischemia-induced neurodegeneration: mechanisms and insights.Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?Perihematomal edema as predictor of outcome.Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Brain iron overload following intracranial haemorrhage.Intracerebral hemorrhage: a multimodality approach to improving outcome.Treatment of intracerebral hemorrhage-is the glass half full or half empty?Bipyridine, an iron chelator, does not lessen intracerebral iron-induced damage or improve outcome after intracerebral hemorrhagic stroke in rats.Injury mechanisms in acute intracerebral hemorrhage.Recent progress in translational research on neurovascular and neurodegenerative disorders.Deferoxamine therapy for intracerebral hemorrhage: A systematic review.A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research.Research Progress in Understanding the Relationship Between Heme Oxygenase-1 and Intracerebral Hemorrhage

P2860

Q24200865-CA40D567-0EEC-4AEA-94E8-927857D3E987 Q26748764-EF367303-F3CB-4DD0-8D3C-D0B718BBACAE Q26769071-C514CE7B-2AC4-44FE-8A1C-705E6796595C Q26863224-BB6C67F5-AD62-49A8-89F4-A8F5C54344E6 Q26863595-A51FEA40-C118-4BE0-947F-06D8336CE22F Q28073307-BAA295BE-22ED-4A61-BCB1-DB813B4B6CCA Q33357329-86D09F19-B3C7-4916-9D49-F68360EC16E6 Q33862295-79919BE3-C0D0-42F4-9047-C2CFC94DD50D Q35088391-B43495CD-AE3C-4E4C-8F79-6E0533DCC6D0 Q35123058-A6053D4D-8284-43B2-BB5D-6F647A8ED8FA Q35391420-AF2A2337-CC35-46A6-A536-769718736039 Q35729599-599581AC-AA0C-4502-B513-3CD782C9BF86 Q35729668-8400147D-D641-426D-B66E-2DBECB04A50C Q36235797-3A944202-8378-4E80-AD84-92F2383E07B4 Q36460054-BA08B9FC-0E4E-4DB6-ABDD-E7D42C9FFA15 Q36707641-5BE8F83D-E382-470B-9781-FF10037F75CE Q36757460-0DA21D1A-9614-454F-A1DE-2BD8D780C285 Q37095550-4A60EF43-108D-4F4D-97B3-5952C16164FA Q37179920-66704A7E-39B0-4F12-966A-58EC7952AFF8 Q37251286-1BD92AEF-AA03-4FB2-A97D-2FA452301EC8 Q37360337-71F43396-50BF-4B35-BF7A-F859F547DC22 Q37448194-623CACFD-B717-4527-938E-F9A022BE155A Q37598901-2E33D043-847C-4E3C-8BD0-7D89BE33CD97 Q37598917-F703191F-D71B-4C27-9717-3B6763B4C497 Q37652936-C16A89A2-9988-4DC0-8586-72CB2BB1FFA6 Q37735698-6964455F-0D9E-43E2-B588-C5D17E6E9C95 Q38173306-36AF815D-B503-434E-BFDB-DE310BAFB4EB Q38194946-89FF4FCA-DD82-4638-9907-C2919668CD86 Q38682340-A790BF7C-5E84-4A81-ABE4-B04CBD3FDAAE Q38730845-0759ED27-87D7-429A-8214-3223E4115A7C Q39179797-31C67E67-1883-4C65-9E05-EAEC28D12C63 Q41678608-C2C5B5B6-DC9A-452F-98B8-2D276F74BDDA Q42043560-D62880A7-C994-4FAB-911D-7725B60C75EF Q44199174-A11149FD-E372-4622-9D6A-EA0212127338 Q46459206-BA584BC1-231F-47D2-BF95-54917AB11438 Q48097259-C5D05A0C-53AF-4B9F-8D78-D65D2CB8F31C Q48714516-1C8F6C20-5C71-41D0-8E15-74B9B38BA8A7 Q53276190-203E3675-157B-4C82-8A22-96DC60274B0B Q55419507-36D5E32C-82BF-41F5-8EFB-3660C06E2A6C Q58735364-DA8C4806-FA6C-4639-B662-2A639A32EBF8

P2860

Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage

http://www.wikidata.org/entity/Q35449198

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety and tolerability of def ...... acute intracerebral hemorrhage

@ast

Safety and tolerability of def ...... acute intracerebral hemorrhage

@en

type

label

Safety and tolerability of def ...... acute intracerebral hemorrhage

@ast

Safety and tolerability of def ...... acute intracerebral hemorrhage

@en

prefLabel

Safety and tolerability of def ...... acute intracerebral hemorrhage

@ast

Safety and tolerability of def ...... acute intracerebral hemorrhage

@en

P1433

Q35449198-112B3E70-A5CF-4B1D-AE8C-2C90782147A6

P1476

Q35449198-3808B64C-9D9E-4FD2-B63B-DAE055FA5919

P2093

Q35449198-10524132-0A53-43CA-9908-4D668CE82819

Q35449198-10526879-4C5A-4204-BCE3-755C9D0D14E4

Q35449198-3E95CC5F-0A2E-4505-9BB7-2D8CD8773A5A

Q35449198-451F60F7-8CD0-4B6E-8504-5A56B3AEDC55

Q35449198-5BAD18C4-A265-4291-B894-F40135B8F649

Q35449198-757D9676-8875-4A3A-9AB1-F9A5B20E7688

Q35449198-A9FE170F-F2BE-47B0-A6A9-72A73D5D6FA4

Q35449198-D0C511E9-C4B5-4178-A90E-B3652DB0E1A4

Q35449198-D4445073-DAFE-404A-97F3-BEA083592E96

Q35449198-E43133F7-693E-486B-BAF5-2504598FF01A

P2860

Q35449198-0B502C42-563D-4D2B-8C44-D7D4B3FE695F

Q35449198-150C4731-0C41-460A-8C23-8E52899DFCBD

Q35449198-19B6C6F3-5D8D-40D4-BDE1-5B3C3479097E

Q35449198-2B2D453F-F006-4F21-86DF-C45A7EC9BC9F

Q35449198-33491120-560B-4438-A3D6-2C422378A07F

Q35449198-3BF52C99-CCD5-4633-8BA5-8A35DABA3B39

Q35449198-3E4D3E20-C8E9-461A-A1AF-2FF4BF990251

Q35449198-3F59553A-FF1B-407B-9DE3-19680B6E8B7D

Q35449198-4A7F4938-A1A3-448A-B50D-2F0CA8313B4A

Q35449198-4D10F623-10AE-43EA-B8EE-615A79E5B368

P304

Q35449198-56874EFF-DCF3-4692-8616-8A4911A874AE

P31

Q35449198-443D97BC-99E0-4295-95C0-78E657F2954F

P356

Q35449198-1B569C8A-FD40-4FD0-9B80-BD5DC0C04A42

P407

Q35449198-DFD658DE-417E-406C-9105-532E6E33FFBC

P433

Q35449198-FC1DFF2E-8F78-4AFB-86DF-A24ACF267435

P478

Q35449198-EEBADFD7-252F-4108-B8BD-440CD698CEAD

P50

Q35449198-0D037309-0084-4A7D-86B4-A83B7A6A8A8F

P577

Q35449198-40711089-7445-4F04-B7E1-99A92F8A5A76

P698

Q35449198-AB0EC7CE-EBC2-4033-9A59-32CCE1D1ECC9

P932

Q35449198-4D3D23A4-E5EB-4022-837D-105672936BF0

P356

STROKEAHA.111.617589

P1433

P1476

Safety and tolerability of def ...... acute intracerebral hemorrhage

@en

P2093

Bonnie Waldman

http://www.w3.org/2001/XMLSchema#string

Deferoxamine Mesylate in Intracerebral Hemorrhage Investigators

http://www.w3.org/2001/XMLSchema#string

Guohua Xi

http://www.w3.org/2001/XMLSchema#string

Joao Gomes

http://www.w3.org/2001/XMLSchema#string

Joshua N Goldstein

http://www.w3.org/2001/XMLSchema#string

Lewis B Morgenstern

http://www.w3.org/2001/XMLSchema#string

Magdy Selim

http://www.w3.org/2001/XMLSchema#string

Michel Torbey

http://www.w3.org/2001/XMLSchema#string

Sharon Yeatts

http://www.w3.org/2001/XMLSchema#string

Steven Greenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Progression of mass effect after intracerebral hemorrhage

Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies.

Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line.

Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats

Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration

Iron regulatory protein-2 knockout increases perihematomal ferritin expression and cell viability after intracerebral hemorrhage.

The relationship between hematoma iron content and perihematoma edema: an MRI study.

Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury

Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.

Natural history of perihematomal edema after intracerebral hemorrhage measured by serial magnetic resonance imaging.

P304

3067-3074

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.111.617589

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Gottfried Schlaug

P577

2011-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21868742

http://www.w3.org/2001/XMLSchema#string

P932

3202043

http://www.w3.org/2001/XMLSchema#string